Form 4: Avidity Legal Chief Sells Shares in Novartis Merger

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Summary

• John B. Moriarty, Chief Legal Officer of Avidity Biosciences, Inc., reported the disposal of 92,054 shares of Common Stock.
• The disposal also included 50,000 stock options with an exercise price of $31.42 and 160,000 stock options with an exercise price of $44.57.
• These transactions are pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Avidity Biosciences, Inc. and Novartis AG.
• Stock options were disposed of in exchange for a cash payment equal to the excess of the merger consideration of $72.00 per share over their respective exercise prices.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Avidity Biosciences' shareholders, as it confirms the execution of a merger that provides a clear cash value for their equity holdings, indicating a successful exit for the company.

Positives

• The merger consideration of $72.00 per share provides a clear valuation for Avidity Biosciences' equity holders.
• The disposal of options for cash at a premium to exercise price indicates a successful realization of value for option holders.

Future Outlook

The future outlook for Avidity Biosciences as an independent entity is defined by its acquisition by Novartis AG, with this filing detailing the execution of equity disposals in accordance with the merger agreement.

Industry Context

StockSavvy.ai notes that mergers and acquisitions are a common strategic move in the biotechnology and pharmaceutical sectors, where larger companies like Novartis often acquire innovative smaller firms such as Avidity Biosciences to expand their pipeline and technology portfolio. This Form 4 filing represents a procedural step in the finalization of such an acquisition, reflecting the integration of Avidity's equity into Novartis's structure.

Comparison to Industry Standards

• Merger consideration of $72.00 per share is typically at a premium to the pre-announcement trading price, which is standard practice in industry acquisitions to incentivize shareholder approval.
• The disposal of insider equity holdings as part of a merger agreement is a standard operational procedure, ensuring all equity interests are settled according to the agreed-upon terms.

Stakeholder Impact

• Shareholders: Will receive $72.00 per share in cash for their common stock.
• Employees (equity holders): Those with stock options will receive cash payments for the in-the-money value of their options, as exemplified by the Chief Legal Officer's transaction.

Next Steps

• Completion of the merger with Novartis AG, leading to Avidity Biosciences' integration or delisting.
• Further insider transaction reports may follow as other executives and directors settle their equity holdings related to the merger.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis, Merger Agreement, Insider Trading, Stock Options, Common Stock, SEC Form 4, Biotechnology, Acquisition